Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Amarex Clinical Research guides its client to phase II of FDA trials
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Subscribe To Our Newsletter & Stay Updated
